Trifluoperazine 1mg tablets

দেশ: যুক্তরাজ্য

ভাষা: ইংরেজি

সূত্র: MHRA (Medicines & Healthcare Products Regulatory Agency)

সক্রিয় উপাদান:

Trifluoperazine hydrochloride

থেকে পাওয়া:

Creo Pharma Ltd

এটিসি কোড:

N05AB06

INN (আন্তর্জাতিক নাম):

Trifluoperazine hydrochloride

ডোজ:

1mg

ফার্মাসিউটিকাল ফর্ম:

Oral tablet

প্রশাসন রুট:

Oral

শ্রেণী:

No Controlled Drug Status

প্রেসক্রিপশন টাইপ:

Valid as a prescribable product

পণ্য সারাংশ:

BNF: 04020100; GTIN: 5060222600445

তথ্য লিফলেট

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
TRIFLUOPERAZINE 1MG AND 5MG TABLETS
(Trifluoperazine Hydrochloride)
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or pharmacist.
•
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
•
If you get any side effects talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET:
1.
What Trifluoperazine is and what it is used for
2.
What you need to know before you take Trifluoperazine
3.
How to take Trifluoperazine
4.
Possible side effects
5.
How to store Trifluoperazine
6.
Contents of the pack and other information
1 WHAT TRIFLUOPERAZINE IS AND WHAT IT IS USED FOR
Trifluoperazine belongs to a group of medicines called phenothiazines.
They act on the central
nervous system and produce a calming effect, relieving anxiety and
tension.
Trifluoperazine is used for the following:
Low dose
•
For short term treatment of anxiety and agitation
•
To treat feeling or being sick (nausea and vomiting)
High dose
•
To treat and prevent relapse of mental disorders such as schizophrenia
•
To treat severe agitation, or mental disorders where dangerous or
impulsive behaviour may be
likely
2 WHAT YOU NEED TO KNOW BEFORE YOU TAKE TRIFLUOPERAZINE
DO NOT TAKE TRIFLUOPERAZINE IF:
•
You are allergic (hypersensitive) to Trifluoperazine, other
phenothiazines or any of the other
ingredients of this medicine (listed in Section 6)
•
You have loss of consciousness (comatose state)
•
You have slower breathing or heartbeat, loss of motor skills, unclear
speech, thinking or vision
(CNS depression)
•
You have an untreated growth on your adrenal gland (phaeochromocytoma)
•
You have blood problems
•
You have liver problems
•
Y

পণ্য বৈশিষ্ট্য

SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Trifluoperazine Tablets 1 mg
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Trifluoperazine hydrochloride 1.2 mg BP (equivalent to trifluoperazine
1 mg)
Excipient(s) with known effect – Sucrose and Lactose
For the full list of excipients, see section 6.1.
3
PHARMACEUTICAL FORM
Tablet
Blue sugar coated tablet.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Low dosage: ‘Trifluoperazine’ is indicated as an adjunct in the
short-term
management of anxiety states, depressive symptoms secondary to
anxiety, and
agitation. It is also indicated in the symptomatic treatment of nausea
and
vomiting.
High dosage: ‘Trifluoperazine’ is indicated for the treatment of
symptoms
and prevention of relapse in schizophrenia and in other psychoses,
especially
of the paranoid type, but not in depressive psychoses. It may also be
used as
an adjunct in the short-term management of severe psychomotor
agitation and
of dangerously impulsive behaviour in, for example, mental
subnormality.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
POSOLOGY
ADULTS
Low dosage:_ _2-4 mg a day, given in divided doses, according to the
severity of the
patient's condition. If necessary, dosage may be increased to 6 mg a
day, but above
this level extrapyramidal symptoms are more likely to occur in some
patients.
High dosage: The recommended starting dose for physically fit adults
is
5 mg twice a day; after a week this may be increased to 15 mg a day.
If necessary,
further increases of 5 mg may be made at three-day intervals, but not
more often.
When satisfactory control has been achieved, dosage should be reduced
gradually
until an effective maintenance level has been established.
As will all major tranquillisers clinical improvement may not be
evident for several
weeks after starting treatment and there may also be a delay before
recurrence of
symptoms after stopping treatment. Gradual withdrawal from high dosage
treatments
is advisable.
_ _
ELDERLY
Reduce starting dose in elderly or frail p